Sensitivities of methods in patients with melanoma were very good for PD-L1, CD8TILs, and CD4TILs biomarkers (TILs: 97.30%; M: 96.43%, 89.13%, and 84.31%, p < 0.001 (Table 3, Figure 6). This evidence concerns the gene CD274 and melanoma.